Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma : a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 ; 19 : 3312-22.
Katsumata N, Fujiwara Y, Kamura T, et al. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy : a Phase II Study of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol. 2008 ; 38 : 777-85.
Wang-Gillam A, Li CP, Bodoky G, et al ; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) : a global, randomised, openlabel, phase 3 trial. Lancet. 2016 ; 387 : 545-57.
Yamaguchi K, Iwasa S, Hirao M, et al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF) : Results from the advanced gastric cancer expansion cohort. J Clin Oncol. 2021 ; 39(15 Suppl.): abstr 4025.
Liu Y, Chen XG, Yang PP, et al. Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy. Biomacromolecules. 2019 ; 20 : 882-92.